Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840451 | 0.87 | KDM4E (0.60) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL8298056 | 0.86 | KDM4E (0.53) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL10630944 | 0.84 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2PBRM1HDAC1 | |
| SCHEMBL27371604 | 0.83 | ITGB3 (0.54) | KDM4EALDH1A1SMN1; SMN2PBRM1HDAC1 | |
| SCHEMBL29780425 | 0.82 | KDM4E (0.56) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL6160025 | 0.82 | MAPK1 (0.60) | KDM4EALDH1A1HPGDSMN1; SMN2PBRM1 | |
| SCHEMBL2398642 | 0.82 | KDM4E (0.67) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL9576605 | 0.81 | LMNA (0.62) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| SCHEMBL12516004 | 0.81 | SMN1; SMN2 (0.62) | KDM4EALDH1A1SMN1; SMN2PBRM1NPSR1 | |
| SCHEMBL29944886 | 0.81 | KDM4E (0.62) | KDM4EALDH1A1SMN1; SMN2PBRM1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019182070-A1 | LIQUID CRYSTAL ALIGNING AGENT, POLYMER FOR OBTAINING SAME, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学株式会社 | 2019-09-26 | — | — | WO | disclosed |
| US-9073966-B2 | Inhibition of sweat malodor | FIRMENICH SA (CH) | 2015-07-07 | — | — | US | disclosed |
| CN-101107263-B | Inhibition of sweat malodour | FIRMENICH & CIE | 2014-08-27 | — | — | CN | disclosed |
| US-20120244098-A1 | INHIBITION OF SWEAT MALODOR | FIRMENICH SA (CH) | 2012-09-27 | — | — | US | disclosed |
| EP-1846436-B1 | INHIBITION OF SWEAT MALODOUR | FIRMENICH & CIE (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-8206692-B2 | Inhibition of sweat malodor | FIRMENICH SA (CH) | 2012-06-26 | — | — | US | disclosed |
| US-20080025935-A1 | INHIBITION OF SWEAT MALODOR | FIRMENICH SA (CH) | 2008-01-31 | — | — | US | disclosed |
| CN-101107263-A | Inhibition of sweat malodour | FIRMENICH & CIE (CH) | 2008-01-16 | — | — | CN | disclosed |
| EP-1846436-A2 | INHIBITION OF SWEAT MALODOUR | Firmenich S.A. (CH) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006079934-A2 | INHIBITION OF SWEAT MALODOUR | FIRMENICH SA (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| CN-1085980-C | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 2002-06-05 | — | — | CN | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| CN-1201454-A | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 1998-12-09 | — | — | CN | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
| EP-0661994-A1 | METHOD OF PROPHYLAXIS OF ACUTE RENAL FAILURE | GENENTECH, INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994006461-A1 | METHOD OF PROPHYLAXIS OF ACUTE RENAL FAILURE | GENENTECH, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244098-A1 | INHIBITION OF SWEAT MALODOR | SQOR, MAL2, TST | KDM4E 3540/4885MAPT 3985/4885HIF1A 4265/4885 |
| US-20080025935-A1 | INHIBITION OF SWEAT MALODOR | MAL2, SQOR, TST | KDM4E 3485/4885MAPT 3758/4885HIF1A 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.